Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

CD20 Protein Immunohistochemistry-Positive/Flow Cytometry-Negative Diffuse Large B-Cell Lymphoma—Analyses of the Molecular Mechanisms and Rituximab Effectiveness

Takashi Tokunaga, MD, Akihiro Tomita, MD, PhD, Junji Hiraga, MD, PhD, Takumi Sugimoto, MD, PhD, Kazuyuki Shimada, MD, PhD, Keiki Sugimoto, Tomohiro Kinoshita, MD, PhD, Tomoki Naoe, MD, PhD.

Blood (2011) 118 (21): 2659.

https://doi.org/10.1182/blood.V118.21.2659.2659

Published: 2011

Journal Articles

CD20-Negative Phenotypic Change In B-Cell Lymphoma Cells After Using Rituximab: Possibility of a Particular Clinicopathologic Phenomenon Post-Rituximab Extranodal CD20-Negative Lymphoma

Akihiro Tomita, MD, PhD, Takashi Tokunaga, MD, Chisako Iriyama, MD, Kazuyuki Shimada, MD, PhD, Junji Hiraga, MD, PhD, Takumi Sugimoto, MD, PhD, Hitoshi Kiyoi, MD, PhD, Shigeo Nakamura, MD, PhD, Tomohiro Kinoshita, MD, PhD, Tomoki Naoe, MD, PhD

Blood (2010) 116 (21): 2874.

https://doi.org/10.1182/blood.V116.21.2874.2874

Published: 2010

Journal Articles

Discrepancy of CD20 Protein Expression In IHC and FCM Analyses In Primary B-Cell Lymphoma: Relationship Between FCM-Negative Phenotype and Rituximab Binding with Lymphoma Cells

Takashi Tokunaga, MD, Akihiro Tomita, MD, PhD, Kazuyuki Shimada, MD, PhD, Junji Hiraga, MD, PhD, Takumi Sugimoto, MD, PhD, Naoe Goto, MD, PhD, Tsuyoshi Takami, MD, PhD, Tomohiro Kinoshita, MD, PhD, Tomoki Naoe, MD, PhD

Blood (2010) 116 (21): 5087.

https://doi.org/10.1182/blood.V116.21.5087.5087

Published: 2010

Journal Articles

MS4A1 (CD20) Gene Expression Is Down-Regulated by Recruiting the Histone Deacetylase Protein Complex to the Promoter in the CD20-Negative B-Lymphoma Cells After Treatment with Rituximab.

Takumi Sugimoto, MD, Akihiro Tomita, MD, Ph.D., Junji Hiraga, MD, Ph.D., Kazuyuki Shimada, MD, Ph.D., Hitoshi Kiyoi, MD, Ph.D., Tomohiro Kinoshita, MD, Ph.D., Tomoki Naoe, MD, Ph.D.

Blood (2009) 114 (22): 1286.

https://doi.org/10.1182/blood.V114.22.1286.1286

Published: 2009

Journal Articles

Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance

Junji Hiraga, Akihiro Tomita, Takumi Sugimoto, Kazuyuki Shimada, Masafumi Ito, Shigeo Nakamura, Hitoshi Kiyoi, Tomohiro Kinoshita, Tomoki Naoe

Blood (2009) 113 (20): 4885–4893.

https://doi.org/10.1182/blood-2008-08-175208

Published: 2009

Includes: Supplemental data

Journal Articles

Relationship Between Post-Translational Modification of CD20 Protein and the Responsiveness to Rituximab Treatment

Takumi Sugimoto, MD, Akihiro Tomita, MD, Kazuyuki Shimada, MD, Junji Hiraga, MD, Hitoshi Kiyoi, MD, Tomohiro Kinoshita, MD, Tomoki Naoe, MD

Blood (2008) 112 (11): 2667.

https://doi.org/10.1182/blood.V112.11.2667.2667

Published: 2008

Journal Articles

Exchange of International Staging System for Durie&Salmon Staging System in Therapeutic Strategy for Multiple Myeloma.

Shingo Kurahashi, MD, Hiroto Narimatsu, MD, Takumi Sugimoto, MD, Isamu Sugiura, MD, PhD

Blood (2005) 106 (11): 5167.

https://doi.org/10.1182/blood.V106.11.5167.5167

Published: 2005

NARROW

CD20 Protein Immunohistochemistry-Positive/Flow Cytometry-Negative Diffuse Large B-Cell Lymphoma—Analyses of the Molecular Mechanisms and Rituximab Effectiveness

CD20-Negative Phenotypic Change In B-Cell Lymphoma Cells After Using Rituximab: Possibility of a Particular Clinicopathologic Phenomenon Post-Rituximab Extranodal CD20-Negative Lymphoma

Discrepancy of CD20 Protein Expression In IHC and FCM Analyses In Primary B-Cell Lymphoma: Relationship Between FCM-Negative Phenotype and Rituximab Binding with Lymphoma Cells

MS4A1 (CD20) Gene Expression Is Down-Regulated by Recruiting the Histone Deacetylase Protein Complex to the Promoter in the CD20-Negative B-Lymphoma Cells After Treatment with Rituximab.

Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance

Relationship Between Post-Translational Modification of CD20 Protein and the Responsiveness to Rituximab Treatment

Exchange of International Staging System for Durie&Salmon Staging System in Therapeutic Strategy for Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

CD20 Protein Immunohistochemistry-Positive/Flow Cytometry-Negative Diffuse Large B-Cell Lymphoma—Analyses of the Molecular Mechanisms and Rituximab Effectiveness

CD20-Negative Phenotypic Change In B-Cell Lymphoma Cells After Using Rituximab: Possibility of a Particular Clinicopathologic Phenomenon Post-Rituximab Extranodal CD20-Negative Lymphoma

Discrepancy of CD20 Protein Expression In IHC and FCM Analyses In Primary B-Cell Lymphoma: Relationship Between FCM-Negative Phenotype and Rituximab Binding with Lymphoma Cells

MS4A1 (CD20) Gene Expression Is Down-Regulated by Recruiting the Histone Deacetylase Protein Complex to the Promoter in the CD20-Negative B-Lymphoma Cells After Treatment with Rituximab.

Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance

Relationship Between Post-Translational Modification of CD20 Protein and the Responsiveness to Rituximab Treatment

Exchange of International Staging System for Durie&Salmon Staging System in Therapeutic Strategy for Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only